Known safety concerns, contraindications, and risk factors.
GHK-Cu injectable use is investigational. The FDA has placed injectable GHK-Cu in Category 2, restricting legal compounding for systemic use in the United States. GHK-Cu is strictly contraindicated for individuals with Wilson's Disease and active malignancies. The information presented here is for educational and research purposes only. Consult a qualified healthcare provider before considering any peptide therapy.
Wilson's Disease
Absolute contraindication. Individuals with this genetic copper metabolism disorder already struggle with toxic copper accumulation. GHK-Cu therapy could be life-threatening.
Active or Suspected Malignancies
Contraindicated due to GHK-Cu's pro-angiogenic effect (VEGF stimulation). The peptide could theoretically support tumor growth by increasing blood supply to existing solid tumors, particularly hormone-sensitive varieties.
Active Liver Disease or Cholestasis
Since the liver is the primary organ for copper metabolism and excretion, impaired liver function significantly increases the risk of chronic copper toxicity.
Pregnancy and Breastfeeding
Universally contraindicated due to a lack of safety data regarding the developing fetus or transfer into breast milk.
Pediatric Use (Under 18)
Use is generally restricted to those 18 and older because the effects of exogenous GHK-Cu on developmental growth pathways are unknown.